BioPharmX recently announced financial results for the first quarter ending April 30 and research updates on BPX-01, a topical antibiotic for acne.
The specialty pharmaceutical company focusing on dermatology and women’s health announced that it has completed full-patient enrollment in a phase 2a study of BPX-01, which will assess safety of the product in 30 patients, according to a press release. Reduction of P. acnes and cutaneous tolerance of the BPX-01 formulation are study endpoints.
The company also announced it was set to commence a phase 2b study of BBX-01, expected to begin in July, to assess efficacy of the product on lesions caused by P. acnes, according to the release.
BioPharmX announced it had total operating expenses of $4.5 million for quarter, compared with total operating expenses of $3.2 million for the first quarter of the prior year, with the increase primarily from funding for the company’s acne drug clinical trials, according to the release.
Net loss of $4.5 million, or $0.17 per share, was reported for the first quarter, compared with a net loss of $3.9 million, or $0.33 per share, during the first quarter a year earlier.